STOCK TITAN
  1. Home
  2. News
  3. ANIP

ANI Pharmaceuticals Inc - ANIP STOCK NEWS

Welcome to our dedicated news page for ANI Pharmaceuticals (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on ANI Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANI Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANI Pharmaceuticals's position in the market.

News
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
Rhea-AI Summary
ANI Pharmaceuticals, Inc. received FDA approval for the Abbreviated New Drug Application for Indomethacin Oral Suspension, a generic version of the Reference Listed Drug Indocin® Oral Suspension. The U.S. market for Indomethacin OS is valued at $4.1 million annually. The FDA granted Indomethacin OS a Competitive Generic Therapy designation with 180-day exclusivity. ANI holds the second highest number of CGT approvals in the U.S. Generics market, showcasing their strong R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
fda approval
-
News
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) will be represented by President & CEO Nikhil Lalwani at the Piper Sandler 35th Annual Healthcare Conference in New York City on November 28, 2023. The webcast of the event will be available on the company's website, and 1x1 meetings can be scheduled by contacting corporateaccess@psc.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
News
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced record quarterly net revenues of $131.8 million, a 57.3% year-over-year growth, with net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45. The company raised its full year 2023 guidance for net revenue to $468 million to $478 million and adjusted non-GAAP EBITDA to $128 million to $133 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.64%
Tags
earnings
News
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) will participate in two upcoming healthcare conferences: Truist Securities BioPharma Symposium on November 9, 2023, and Jefferies London Healthcare Conference on November 15, 2023. The company's CEO and CFO will be attending and available for 1x1 meetings. The webcast of the conferences will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences
-
News
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals, Inc. will release its Q3 2023 financial results on November 8th. A conference call will be hosted by the President and CEO, and the Senior VP of Finance and CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
earnings
-
News
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
Rhea-AI Summary
ANI Pharmaceuticals announces FDA approval and commercial availability of a 1-mL vial of Cortrophin Gel for the treatment of acute gouty arthritis flares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
fda approval
News
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
Rhea-AI Summary
ANI Pharmaceuticals to present at Cantor Global Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences
-
News
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
Rhea-AI Summary
ANI Pharmaceuticals receives FDA approval for Estradiol Tablets USP, generating positive business prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
fda approval
-
News
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
Rhea-AI Summary
ANI Pharmaceuticals receives FDA approval for Estradiol Gel, 0.1%
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
fda approval
News
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
ANI Pharmaceuticals to present at H.C. Wainwright conference on September 12, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences
Stock ANIP logo
ANI Pharmaceuticals Inc

Nasdaq:ANIP

ANIP Rankings

#2168 Ranked by Market Cap
#367 Ranked by Stock Gains
N/A Ranked by Dividends

ANIP Stock Data

1.38B
15.04M
11.2%
75.52%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Baudette

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.